Efficacy of adding levofoxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: Study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)

Advanced pancreatic cancer is one of the leading causes of cancer-related deaths. This prospective study aims to evaluate whether the addition of antibiotics improves the treatment efficacy of GEM/nabPTX as a first-line chemotherapy in patients with advanced pancreatic cancer.